Page 4 - Denis Bedoret News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DGAP-News: Imcys ... DGAP-News: Imcyse Enters into Research Collaboration and License Agreement for its ImotopeTM Technology with Pfizer in Rheumatoid Arthritis vom 03.02.2021, 14:00 Uhr Bild: pixabay.com DGAP-News: Imcyse SA / Key word(s): Agreement Imcyse Enters into Research Collaboration and License Agreement for its ImotopeTM Technology with Pfizer in Rheumatoid Arthritis 03.02.2021 / 14:00 Imcyse Enters into Research Collaboration and License Agreement for its Imotope TM Technology with Pfizer in Rheumatoid Arthritis Imcyse and Pfizer to collaborate to develop Imotope TM ca...

Press release content from Accesswire. The AP news staff was not involved in its creation. Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes February 3, 2021 GMT LIEGE, BELGIUM / ACCESSWIRE / February 3, 2021 / Imcyse, a clinical-stage biopharmaceutical company pioneering the development of a new class of active and specific immunotherapies for the treatment of severe autoimmune diseases, today announced the first patients’ treatment in the IMCY-0098 Proof of ACtion in Type 1 Diabetes (T1D) (IMPACT) study with IMCY-0098. The IMPACT trial, in co...